Precigen (PGEN) closed at $5.06 on November 4, 2026, down 3.7% from the previous close, on volume of 9,743,467 shares (30-day average 5,636,502).
Data as of November 4, 2026.
Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Adaptive Biotechnologies (ADPT)
TipRanks (Thu, 5-Nov 9:10 AM ET)
Precigen GAAP EPS of $0.08 in-line, revenue of $74.1M beats by $2.54M
Seeking Alpha News (Wed, 4-Nov 5:05 PM ET)
PRNewswire (Wed, 4-Nov 4:05 PM ET)
Seeking Alpha News (Tue, 3-Nov 11:17 AM ET)
Precigen’s Commercial Momentum Supports Reiterated Buy Rating; $18 Price Target Maintained
TipRanks (Mon, 2-Nov 1:05 PM ET)
Precigen craters on Inovio Voceryq immunotherapy approval
Seeking Alpha News (Mon, 2-Nov 11:14 AM ET)
Precigen to Announce Third Quarter 2026 Financial Results and Provide Business Updates on November 4
PRNewswire (Wed, 28-Oct 4:06 PM ET)
Market Chameleon (Mon, 21-Sep 3:34 AM ET)
Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform
PRNewswire (Mon, 21-Sep 7:00 AM ET)
ACCESS Newswire (Tue, 25-Aug 7:00 AM ET)
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Precigen trades on the NASDAQ stock market under the symbol PGEN.
As of November 5, 2026, PGEN stock price declined to $3.98 with 11,434,211 million shares trading.
PGEN has a beta of 0.85, meaning it tends to be less sensitive to market movements. PGEN has a correlation of 0.02 to the broad based SPY ETF.
PGEN has a market cap of $1.42 billion. This is considered a Small Cap stock.
Last quarter Precigen reported $74 million in Revenue and $.08 earnings per share. This beat revenue expectation by $2 million and met earnings estimates .
In the last 3 years, PGEN traded as high as $8.98 and as low as $.65.
The top ETF exchange traded funds that PGEN belongs to (by Net Assets): VTI, XBI, IWM, VXF, VTWO.
PGEN has underperformed the market in the last year with a price return of +2.6% while the SPY ETF gained +10.9%. PGEN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -39.1% and -39.7%, respectively, while the SPY returned -3.7% and -4.1%, respectively.
PGEN support price is $4.82 and resistance is $5.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PGEN shares will trade within this expected range on the day.
